References
- A. R. Paradkar, B. Chauhan, S. Yamamura and A. P. Pawar, Preparation and characterization of glassy celecoxib, Drug Dev. Ind. Pharm.29 (2003) 739--744; DOI: 10.1081/DDC-120021773.
- P. Gupta, G. Chawala and A. K. Bansal, Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility, Mol. Pharm.1 (2004) 406--413; DOI: 10.1021/mp049938f.
- M. K. Gupta., A. Vanwert and R. H. Bogner, Formation of physically stable amorphous drugs by milling with Neusilin, J. Pharm. Sci.92 (2003) 536--551; DOI: 10.1002/jps.10308.
- D. Q. Craig, P. G. Royall, V. L. Kett and M. L. Hopton, The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems, Int. J. Pharm.179 (1999) 179--207; DOI: 10.1016/S0378-5173(98)00338-X.
- A. A. Ambike, K. R. Mahadik, A. R. Paradkar, Stability study of amorphous valdecoxib, Int. J. Pharm.282 (2004) 151--162; DOI: 10.1080/03639040500272025.
- A. Paradkar, M. Maheshwari, R Kamble, I. Grimsey and P. York, Design and evaluation of celecoxib porous particles using melt sonocrystallization, Pharm. Res.23 (2005) 1395--1400; DOI: 10.1007/s11095-006-0020-4.
- D. Law, S. L. Krill, E. A. Schmitt, J. J. Fort, Y. H. Qiu, W. L. Wang and W. R. Porter, Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions, J. Pharm. Sci.90 (2001) 1015--1025; DOI: 10.1002/jps.1054.
- H. Suzuki and H. Sunada, Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers, Chem. Pharm. Bull.46 (1998) 482--487.
- S. L. Shimpi, B. Chauhan, K. R. Mahadik and A. R. Paradkar, Stabilization and improved in-vivo performance of amorphous etoricoxib using gelucier 50/13, Pharm. Res.22 (2005) 1727--1734; DOI: 10.1007/s11095-005-6694-1.
- P. Gupta, V. K. Kakamanu and A. K. Bansal, Stability and solubility of celecoxib-PVP amorphous dispersions: molecular perspective, Pharm. Res.21 (2004) 1762-1769; DOI:10.1023/B:PHAM. 0000045226.42859.b8.
- P. Gupta, R. Thilagavathi, A. K. Chakraborti and A. K. Bansal, Role of molecular interaction in stability of celecoxib-PVP amorphous systems, Mol. Pharm.2 (2005) 384--391.
- J. Akbuga, A. Gursoy and F. Yetimoglu, Preparation and properties of tablets prepared from furosemide-PVP solid dispersion systems, Drug Dev. Ind. Pharm.14 (1988) 2091--2108.
- K. R. Morris, U. J. Griesserb, C. J. Eckhardt and J. G. Stowell, Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes, Adv. Drug Deliv. Rev.48 (2001) 91--114; DOI: 10.1016/S0169-409X(01)00100-4.
- T. Matsumoto, N. Kaneniwa, S. Higuchi and M. Otsuka, Effects of temperature and pressure during compression on the polymorphic transformation and crushing strength of chlorpropamide tablets, J. Pharm. Pharmacol.43 (1991) 74--78.
- V. Andronis and G. Zografi, The molecular mobility of supercooled amorphous indomethacin as a function of temperature and relative humidity, Pharm. Res.15 (1998) 835--842.
- M. Otsuka, M. Nakanishi and Y. Matsuda. Effects of crystalline form on compression mechanism of phenobarbital polymorphs, Drug Dev. Ind. Pharm.25 (1999) 205--215.
- C. Lefebvre, A. M. Guyot-Hermann, M. Draguet-Bruchmans and R. Bouche, Polymorphic transitions of carbamazepine during grinding and compression, Drug Dev. Ind. Pharm.12 (1986) 1913--1927.
- H. Chan and E. Doelker, Polymorphic transformation of some drugs under compression, Drug Dev. Ind. Pharm.11 (1985) 315--332.
- A. G. Schmidt, S. Wartewig and K. M. Picker, Potential of carrageenan to protect drugs from polymorphic transformation, Eur. J. Pharm. Biopharm.56 (2003) 101--110; DOI: 10.1016/S0939--6411(03)00037-7.
- K. M. Picker, "Soft tableting": A new concept to tablet pressure sensitive materials, Pharm. Dev. Technol.9 (2004) 107--121; DOI: 10.1081/PDT-120027426.
- United States Pharmacopoeia 24, National Formulary 19, USP Convention, Rockville 2000.